Patents by Inventor Gustav Gaudernack

Gustav Gaudernack has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220127574
    Abstract: The present invention relates to a modified natural killer (NK) cell and its use in personalised medicine. The modified NK cells of the present invention are non-immunogenic, meaning that they are able to be administered to any recipient subject without being rejected by the host immune system (they are “universal”). In a first embodiment the non-immunogenic NK cells are modified to express CD3 to allow a T-cell Receptor (TcR) to be expressed. In a further embodiment the non-immunogenic NK cells are further modified to express a TcR together with the CD3 co-receptor. Co-expression of CD3 with a specific TcR results in the modified NK cells showing antigen-specific cytotoxicity towards target cells. Universal NK cells can thus be targeted against specific antigens, and may thus be used in personalised medicine, particularly in the field of oncology.
    Type: Application
    Filed: September 23, 2021
    Publication date: April 28, 2022
    Inventors: Sébastien Wälchli, Else Marit Inderberg Suso, Gustav Gaudernack, Gunnar Kvalheim
  • Patent number: 11155786
    Abstract: The present invention relates to a modified natural killer (NK) cell and its use in personalised medicine. The modified NK cells of the present invention are non-immunogenic, meaning that they are able to be administered to any recipient subject without being rejected by the host immune system (they are “universal”). In a first embodiment the non-immunogenic NK cells are modified to express CD3 to allow a T-cell Receptor (TcR) to be expressed. In a further embodiment the non-immunogenic NK cells are further modified to express a TcR together with the CD3 co-receptor. Co-expression of CD3 with a specific TcR results in the modified NK cells showing antigen-specific cytotoxicity towards target cells. Universal NK cells can thus be targeted against specific antigens, and may thus be used in personalised medicine, particularly in the field of oncology.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: October 26, 2021
    Assignee: Oslo Universitetssykehus HF
    Inventors: Sébastien Wälchli, Else Marit Inderberg Suso, Gustav Gaudernack, Gunnar Kvalheim
  • Publication number: 20200121771
    Abstract: A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.
    Type: Application
    Filed: December 12, 2019
    Publication date: April 23, 2020
    Inventors: Gustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
  • Publication number: 20200009238
    Abstract: The present invention relates to peptides presented on the cell surface of cells in the MHC class I (MHC I) context in which the invariant chain has been engineered to favor loading of specific antigens and generate CD8+ T-cell activation
    Type: Application
    Filed: September 25, 2019
    Publication date: January 9, 2020
    Inventors: Sebastien P. WÄLCHLI, Tone Fredsvik GREGERS, Else Marit Suso INDERBERG, Gustav GAUDERNACK, Gunnar KVALHEIM, Oddmund BAKKE
  • Publication number: 20190358263
    Abstract: The present invention relates to cancer immunotherapy. In particular, provided herein are compositions and methods for improving the efficacy of cell therapies cancer and other diseases.
    Type: Application
    Filed: December 7, 2017
    Publication date: November 28, 2019
    Inventors: Sebastien Walchli, Else Marit Inderberg, Gunnar Kvalheim, Gustav Gaudernack, Nadia Mensali
  • Publication number: 20190336529
    Abstract: The present invention relates to TCR molecules which recognise neopeptides produced as a result of the cancer-associated “?1A” frameshift mutation in human TGF?RII. The TCR molecules are capable of binding a peptide of SEQ ID NO: 1 when said peptide is presented by a Class I MHC, and comprise an ?-chain domain and a ?-chain domain, each chain domain comprising three CDR sequences, wherein a) CDRs 1, 2 and 3 of the ?-chain domain have the sequences of SEQ ID NOs: 2, 3 and 4 respectively; and b) CDRs 1, 2 and 3 of the ?-chain domain have the sequences of SEQ ID NOs: 5, 6 and 7 respectively, and wherein one or more of said CDR sequences may optionally be modified by substitution, addition or deletion of 1 or 2 amino acids. Nucleic acid molecules encoding such TCRs are provided, as are soluble TCR molecules with these CDR sequences.
    Type: Application
    Filed: May 9, 2017
    Publication date: November 7, 2019
    Applicant: Oslo Universitetssykehus HF
    Inventors: Else Marit Inderberg, Gustav Gaudernack, Sèbastien Wälchli, Gunnar Kvalheim
  • Patent number: 10383928
    Abstract: A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: August 20, 2019
    Assignee: ULTIMOVACS AS
    Inventors: Gustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
  • Publication number: 20190247482
    Abstract: A polypeptide for use in medicine is provided. The polypeptide is administered simultaneously, separately or sequentially with an immune checkpoint inhibitor. The polypeptide comprises at least one polypeptide comprising a region of at least 12 amino acids of a self-antigen or a sequence having at least 80% identity to the region. The polypeptide is less than 100 amino acids in length.
    Type: Application
    Filed: June 2, 2017
    Publication date: August 15, 2019
    Inventors: Gustav Gaudernack, Audun Tornes
  • Publication number: 20180010097
    Abstract: The present invention relates to a modified natural killer (NK) cell and its use in personalised medicine. The modified NK cells of the present invention are non-immunogenic, meaning that they are able to be administered to any recipient subject without being rejected by the host immune system (they are “universal”). In a first embodiment the non-immunogenic NK cells are modified to express CD3 to allow a T-cell Receptor (TcR) to be expressed. In a further embodiment the non-immunogenic NK cells are further modified to express a TcR together with the CD3 co-receptor. Co-expression of CD3 with a specific TcR results in the modified NK cells showing antigen-specific cytotoxicity towards target cells. Universal NK cells can thus be targeted against specific antigens, and may thus be used in personalised medicine, particularly in the field of oncology.
    Type: Application
    Filed: January 22, 2016
    Publication date: January 11, 2018
    Inventors: Sébastien WÄLCHLI, Else Marit Inderberg SUSO, Gustav GAUDERNACK, Gunnar KVALHEIM
  • Patent number: 9757439
    Abstract: There is disclosed at least one peptide suitable for eliciting an immune response, for use in the treatment of cancer. The, or each, peptide corresponds to a fragment of the RAS protein, but has one to three point mutations thereof. The at least one peptide is for use in the treatment of cancer by simultaneous or sequential administration with an anti-metabolite chemotherapeutic agent.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: September 12, 2017
    Assignee: TARGOVAX ASA
    Inventors: Jon Amund Eriksen, Gustav Gaudernack
  • Publication number: 20170232088
    Abstract: A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.
    Type: Application
    Filed: April 27, 2017
    Publication date: August 17, 2017
    Inventors: Gustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
  • Publication number: 20170232087
    Abstract: A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.
    Type: Application
    Filed: April 27, 2017
    Publication date: August 17, 2017
    Inventors: Gustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
  • Patent number: 9657068
    Abstract: A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.
    Type: Grant
    Filed: February 15, 2011
    Date of Patent: May 23, 2017
    Assignee: Ultimovacs AS
    Inventors: Gustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
  • Publication number: 20170106066
    Abstract: The present invention relates to peptides presented on the cell surface of cells in the MHC class I (MHC I) context in which the invariant chain has been engineered to favor loading of specific antigens and generate CD8+ T-cell activation
    Type: Application
    Filed: June 10, 2015
    Publication date: April 20, 2017
    Applicant: UNIVERSITETET I OSLO
    Inventors: Sebastien P. WÄLCHLI, Tone Fredsvik GREGERS, Else Marit Suso INDERBERG, Gustav GAUDERNACK, Gunnar KVALHEIM, Oddmund BAKKE
  • Publication number: 20170065694
    Abstract: There is disclosed at least one peptide suitable for eliciting an immune response, for use in the treatment of cancer. The, or each, peptide corresponds to a fragment of the RAS protein, but has one to three point mutations thereof. The at least one peptide is for use in the treatment of cancer by simultaneous or sequential administration with an anti-metabolite chemotherapeutic agent.
    Type: Application
    Filed: May 5, 2015
    Publication date: March 9, 2017
    Inventors: Jon Amund Eriksen, Gustav Gaudernack
  • Patent number: 8614177
    Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the inventions are also described.
    Type: Grant
    Filed: January 3, 2011
    Date of Patent: December 24, 2013
    Assignee: Gemvax AS
    Inventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Moller, Marianne Klemp Gjertsen, Ingvil Saeterdal
  • Publication number: 20130129760
    Abstract: A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.
    Type: Application
    Filed: February 15, 2011
    Publication date: May 23, 2013
    Inventors: Gustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
  • Publication number: 20120269858
    Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognising and destroying tumour cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.
    Type: Application
    Filed: May 31, 2012
    Publication date: October 25, 2012
    Applicant: GEMVAX AS
    Inventors: Gustav GAUDERNACK, Stein SÆBØE-LARSSEN, Mona MØLLER, Jon Amund ERIKSEN
  • Patent number: 8193326
    Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognizing and destroying tumor cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.
    Type: Grant
    Filed: March 5, 2008
    Date of Patent: June 5, 2012
    Assignee: GemVax AS
    Inventors: Gustav Gaudernack, Stein Sæbøe-Larssen, Mona Møller, Jon Amund Eriksen
  • Publication number: 20110105721
    Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the inventions are also described.
    Type: Application
    Filed: January 3, 2011
    Publication date: May 5, 2011
    Applicant: GEMVAX AS
    Inventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal